JP2023542453A5 - - Google Patents

Info

Publication number
JP2023542453A5
JP2023542453A5 JP2023502638A JP2023502638A JP2023542453A5 JP 2023542453 A5 JP2023542453 A5 JP 2023542453A5 JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023542453 A5 JP2023542453 A5 JP 2023542453A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
group
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034069 external-priority patent/WO2022015418A1/en
Publication of JP2023542453A publication Critical patent/JP2023542453A/ja
Publication of JP2023542453A5 publication Critical patent/JP2023542453A5/ja
Priority to JP2025136537A priority Critical patent/JP2025170319A/ja
Pending legal-status Critical Current

Links

JP2023502638A 2020-07-14 2021-05-25 Sars-cov-2阻害剤 Pending JP2023542453A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136537A JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051474P 2020-07-14 2020-07-14
US63/051,474 2020-07-14
US202063067593P 2020-08-19 2020-08-19
US63/067,593 2020-08-19
PCT/US2021/034069 WO2022015418A1 (en) 2020-07-14 2021-05-25 Sars-cov-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136537A Division JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Publications (2)

Publication Number Publication Date
JP2023542453A JP2023542453A (ja) 2023-10-10
JP2023542453A5 true JP2023542453A5 (cg-RX-API-DMAC7.html) 2024-06-03

Family

ID=76808129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502638A Pending JP2023542453A (ja) 2020-07-14 2021-05-25 Sars-cov-2阻害剤
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Country Status (7)

Country Link
US (1) US20230250134A1 (cg-RX-API-DMAC7.html)
EP (1) EP4182027A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023542453A (cg-RX-API-DMAC7.html)
KR (1) KR20230038485A (cg-RX-API-DMAC7.html)
CN (1) CN116209672A (cg-RX-API-DMAC7.html)
AU (1) AU2021308208A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022015418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368631A4 (en) * 2021-07-07 2025-08-13 Univ Nat Corp Tokyo Medical & Dental PEPTIDE HAVING ANTIVIRAL ACTIVITY, ANTIVIRAL AGENT COMPRISING SAID PEPTIDE, AND METHOD FOR PRODUCING SAID ANTIVIRAL AGENT
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
WO2025101453A1 (en) * 2023-11-07 2025-05-15 University Of Washington De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025221716A1 (en) * 2024-04-17 2025-10-23 University Of Washington Smart mhc: a de-novo designed platform for soluble expression of peptide-receptive class-i mhc in e. coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
CA3178016A1 (en) * 2020-05-27 2021-12-02 University Of Washington Modular and generalizable biosensor platform based on de novo designed protein switches

Similar Documents

Publication Publication Date Title
JP2023506765A5 (cg-RX-API-DMAC7.html)
IL321500A (en) Pre-stabilized hmpv f proteins
JP2022115876A5 (cg-RX-API-DMAC7.html)
JP2023544834A5 (cg-RX-API-DMAC7.html)
JP2023518038A5 (cg-RX-API-DMAC7.html)
JP2023522249A5 (cg-RX-API-DMAC7.html)
TWI250988B (en) Thrombopoietic compounds
JP2023156353A5 (cg-RX-API-DMAC7.html)
ES3064850T3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2021512126A5 (cg-RX-API-DMAC7.html)
ES2210255T3 (es) Metodos para mejorar la actividad biologica de quimiocinas.
JP2023524054A5 (cg-RX-API-DMAC7.html)
JP2025184979A5 (cg-RX-API-DMAC7.html)
JP2019506166A5 (cg-RX-API-DMAC7.html)
RU2018100181A (ru) Модифицированный белок интерлейкина-7 и способы его применения
JP2008507298A5 (cg-RX-API-DMAC7.html)
JP2023528207A5 (cg-RX-API-DMAC7.html)
CN121343934A (zh) 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
JP2024533316A5 (cg-RX-API-DMAC7.html)
JP2018537089A5 (cg-RX-API-DMAC7.html)
JP2025170319A (ja) Sars-cov-2阻害剤
JP2025521082A5 (cg-RX-API-DMAC7.html)
JP2001526242A (ja) Ifnar2/ifn複合体
JP2022551813A5 (cg-RX-API-DMAC7.html)
JP2005505293A5 (cg-RX-API-DMAC7.html)